On May 28, 2026, Chongqing Genrix Biopharmaceutical Co., Ltd. ("Genrix Bio") reported that it signed an exclusive licensing agreement with Chongqing Yaopharma Pharmaceutical Co., Ltd. (" YaoPharma"), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Under the agreement, YaoPharma will obtain exclusive rights in the Greater China region (including Hong Kong, Macau and Taiwan) for the clinical development and commercialization of the anti-BCMA×CD3 bispecific antibody Velitomab Injection (GR1803 Injection), as well as exclusive rights relating to process development and manufacturing. The collaboration aims to integrate the strengths and resources of both parties to accelerate the accessibility of this innovative therapy in China and bring new hope to patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, YaoPharma will pay Genrix Bio upfront and milestone payments of up to RMB 1.82 billion, including an upfront payment of RMB 300 million, up to RMB 300 million in regulatory approval and technology transfer milestone payments, and up to RMB 1.22 billion in sales-based milestone payments tied to net sales. In addition, Genrix Bio will be entitled to tiered royalties ranging from high single-digit to low double-digit percentages based on net sales of GR1803 Injection in the licensed territory. The agreement became effective upon execution and will remain in force until the expiry of the royalty term for the licensed products in the licensed territory.

GR1803 is a bispecific antibody simultaneously targeting BCMA and CD3. It is classified as a Class 1 therapeutic biologic and is intended for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least three prior lines of therapy. In January 2026, GR1803 was submitted to China’s National Medical Products Administration (NMPA) for conditional approval and was accepted for review. It has also been included in the priority review pathway. In addition to the RRMM indication, Genrix is actively exploring the application of GR1803 in autoimmune diseases, with clinical trials for systemic lupus erythematosus progressing steadily. Notably, in June 2025, Genrix entered into an overseas exclusive licensing agreement for GR1803 with Nasdaq-listed Cullinan Therapeutics, Inc., with a total deal value exceeding USD 700 million, demonstrating international recognition of the product’s global clinical development potential.

The collaboration with YaoPharma marks a further step in Genrix Bio’s innovative drug commercialization strategy. By partnering with YaoPharma, another Chongqing-based pharmaceutical company with strong industrial capabilities, Genrix Bio will be able to combine its R&D strengths in GR1803 with YaoPharma’s manufacturing and commercialization expertise. Thus, they can significantly enhance GR1803 Injection’s accessibility and market penetration in China.

The collaboration also lays a solid foundation for broader cooperation between the two parties in the biopharmaceutical sector. Following the anticipated approval and launch of GR1803, the parties are expected to jointly explore other products and therapies for the vast oncology and autoimmune disease markets.

Genrix Bio is an innovative biopharmaceutical company driving to solve significant unmet clinical needs through its strength in antibody discovery technologies. The company focuses on three major therapeutic areas: autoimmune diseases, infectious diseases and oncology. It is committed to the continuous development of monoclonal antibodies, bispecific antibodies, and multispecific antibodies. It has established a fully integrated antibody drug value chain spanning molecular discovery, process development and quality research, clinical development, and large-scale commercialization.

(Press release, Genrix Biopharmaceutical, MAY 28, 2026, View Source [SID1234670976])

On May 28, 2026 Low Institute for Therapeutics (LIFT), a pioneering non-profit clinical research organization, and NorthStar Medical Radioisotopes, LLC (NorthStar), a leading radiopharmaceutical company reported a strategic collaboration to accelerate the development, manufacturing, and clinical translation of Lu177-LT17, a novel Lutetium-177 based radioligand therapy candidate for the treatment of cancer-associated bone disease, including hematologic malignancies and metastatic solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Through the partnership, NorthStar will provide integrated radiopharmaceutical contract development and manufacturing (CDMO) capabilities, including LT17 isotope radiolabeling, analytical development, and current Good Manufacturing Practice (cGMP) manufacturing support. The collaboration will support key translational and regulatory milestones aimed at supporting an Investigational New Drug (IND) application. Once approved, NorthStar will manufacture the clinical supply for planned Phase I first in-human trials.

"Our collaboration with LIFT reinforces NorthStar’s position as a preferred contract development and manufacturing partner across the radiopharmaceutical ecosystem, including with nonprofit and academic-led programs," said Dr. Frank Scholz, President & CEO of NorthStar. "By combining our end-to-end CDMO capabilities with LIFT’s research model, we are helping bring promising new therapies closer to patients who need them most."

Lu177-LT17 is a highly targeted radioligand therapy designed to selectively deliver therapeutic radioisotopes to cancer-induced bone lesions while minimizing exposure to surrounding healthy tissue. The program reflects the growing momentum across the radiopharmaceutical sector as precision oncology and targeted radioligand therapies continue advancing toward broader clinical adoption.

"LIFT was founded with a mandate to advance the groundbreaking discoveries coming out of Purdue University into transformative therapies for patients," said Dr. Stewart Low, Executive Director of LIFT. "Lu177-LT17 is a compelling example of that mandate being put into action. Partnering with NorthStar provides the expertise and infrastructure necessary to advance Lu177-LT17 into the clinic and ultimately, help patients in need."

For NorthStar, the collaboration further expands the company’s role as an integrated radiopharmaceutical partner supporting early development, isotope production and supply, and cGMP manufacturing for emerging radiopharmaceutical programs. NorthStar’s vertically integrated infrastructure was purpose-built to support seamless radiopharmaceutical development, scale-up, and long-term commercialization, enabling programs to advance from early clinical development through commercial readiness within a coordinated operational environment.

(Press release, NorthStar Medical Radiostopes, MAY 28, 2026, View Source [SID1234666184])

On May 28, 2026 Anaveon, a late-stage preclinical biotechnology company focused on reprogramming the immune system for the treatment of autoimmune and inflammatory diseases, reported that new clinical data from its legacy oncology asset ANV600 (sunekafusp alpha) will be presented at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following its strategic pivot to immunology, Anaveon is actively seeking global development and commercialization partners for its oncology portfolio to maximize the potential of these highly differentiated assets.

ANV600 is a first-in-class, non-blocking PD-1-targeted IL-2R-βγ agonist designed to selectively expand tumor-reactive PD-1+ CD8+ effector T cells while reducing the toxicities historically associated with IL-2 therapy. It is compatible with existing Check Point Inhibitors (CPI) and is positioned for use in CPI-resistant and CPI-relapsed patients.

Key results from the EXPAND-1 Phase 1 study will be highlighted in the poster:

The encouraging preliminary antitumor activity observed with ANV600 should be investigated further through additional clinical studies with larger patient populations,
ANV600 is well tolerated as a monotherapy and in combination with pembrolizumab,
A complete response (CR) was observed in a patient with NSCLC (non-small cell lung cancer) previously progressing on CPI and treated with ANV600 monotherapy at 120 µg/kg Q2W. Partial responses (PRs) were reported for two patients treated respectively with 30 µg/kg and 60 µg/kg ANV600 Q2W in combination with pembrolizumab Q3W,
Patients experienced target lesion shrinkage in 29% of patients receiving ANV600 monotherapy and 24% of patients receiving ANV600 plus pembrolizumab,
Disease control defined as Complete Response, Partial Response, or Stable Disease observed in 42% of patients treated with ANV600 monotherapy and 59% of the patients receiving ANV600 and Pembrolizumab,
Recommended Phase 2 dose of 90 µg/kg weekly for 4 weeks followed by 150 µg/kg Q2W established,
Patients Treatment with ANV600 resulted in higher absolute counts of CD8+ T cells and NK cells over regulatory T cells.
"Patients with advanced solid tumors treated with ANV600 derived meaningful clinical benefit, with approximately 24% of patients achieving a Complete Response, Partial Response or durable Stable Disease maintained for at least 18 weeks (≥3 tumor assessments)," said Prof. Dr. med. Markus Jörger of Health Ostschweiz (HOCH) in St. Gallen (Switzerland). "The trial provided a valuable treatment option for patients whose disease had progressed beyond available therapies. ANV600 demonstrated a promising safety-efficacy profile, together with compelling proof-of-mechanism in patients with advanced solid tumors."

ASCO Annual Meeting abstracts may be accessed online via View Source

Presentation Details:
Title: Safety, PK/PD, and efficacy results from Expand-1: A phase 1 dose escalation study of the novel PD-1 targeted IL-2R-βγ agonist sunekafusp alpha (ANV600) as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.
First Author: Markus Joerger
Abstract number: 2587
Session Title: Development Therapeutics- Immunotherapy
Poster board: 377
Location, Date and Time: Hall A, May 30, 2026, 1:30 to 4:30 pm, CDT

"With established clinical benefits and strong interest from current clinical investigators, we believe that ANV600 is ideally suited for a partner with the resources and expertise to bring it forward in CPI-resistant NSCLC and other immuno-oncology indications," added Thaminda Ramanayake, Chief Executive Officer of Anaveon.

Anaveon’s proprietary oncology product portfolio is built around a non-blocking PD-1 targeted cytokine platform. This highly selective "cis-signaling" proximity-activated delivery of cytokines is precise and combinable with Check Point Inhibitors. In addition to ANV600, the platform includes ANV700, a preclinical proximity-activated PD-1-targeted IL-21 fusion protein with potential for synergistic effects when combined with IL-2-based approaches and another undisclosed preclinical program. Included in the oncology portfolio is ANV419, an earlier generation (non-PD-1-targeted) IL-2/anti-IL-2 fusion protein with demonstrated safety in prior clinical studies.

The company is now prioritizing its core immunology pipeline and is open to various partnering structures (license, co-development, or acquisition) for the oncology platform and portfolio.

(Press release, Anaveon, MAY 28, 2026, View Source [SID1234666183])

On May 28, 2026 BPGbio, Inc., a clinical-stage biopharmaceutical company advancing mitochondrial-targeted therapeutics for patients, reported that new clinical progress from its ongoing Phase 2 study of BPM31510 in newly diagnosed glioblastoma multiforme (GBM) will be presented at the upcoming ASCO (Free ASCO Whitepaper) Annual Meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The trial-in-progress poster will be presented by Seema Nagpal, M.D., Principal Investigator of the study and Professor of Neurology and Neurological Sciences at Stanford Medicine.

Abstract Details

Abstract Number: TPS2101
Title: Progress report of a phase 2 study of BPM31510 (a lipid nano dispersion of oxidized CoQ10) with vitamin K in combination with standard of care (SOC) RT and TMZ in glioblastoma multiforme (GBM) patients without prior therapy
Session Type/Title: Poster Session – Central Nervous System Tumors
Poster Board: 461b
Presentation Date & Time: Monday, June 1, 2026 | 1:30 PM – 4:30 PM CDT

The ongoing Phase 2 study is evaluating BPM31510, an investigational lipid nanodispersion formulation of oxidized Coenzyme Q10 (CoQ10), administered with vitamin K1 in combination with standard-of-care radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagnosed GBM who have not received prior therapy.

BPM31510 is designed to target dysregulated mitochondrial metabolism in cancer cells. By modulating mitochondrial function and restoring oxidative balance, BPM31510 aims to induce tumor-selective redox stress while helping preserve healthy tissue metabolism. The investigational therapy seeks to re-engage mitochondrial pathways that may contribute to tumor cell vulnerability in highly aggressive cancers such as glioblastoma. Moreover, the direct targeting of the BCL-2 protein family serves to sensitize patients to radiotherapy.

"The BPM31510 phase I trial delivered pharmacodynamic proof, PET-confirmed reversal of the Warburg effect, shifting tumor metabolism from glycolysis to oxidative phosphorylation at supraphysiologic CoQ10 concentrations. That metabolic reprogramming drives a ROS-mediated, BCL-2–dependent apoptotic cascade that may finally unlock glioblastoma’s mitochondrial vulnerability", said Vivek Subbiah, M.D., Jeffrey and Christina Bird Endowed Chair and Professor of Medicine, Division of Oncology and Associate Director for Drug Development and Precision Oncology at the Stanford Cancer Institute, Stanford University School of Medicine, CA, USA. "For patients with GBM, a devastating disease where median survival remains under two years despite decades of research, the ongoing front-line study is a test of whether this science can translate into a meaningful survival benefit."

Glioblastoma is the most common and aggressive malignant primary brain tumor in adults and is associated with poor survival despite multimodal treatment approaches. Increasing evidence suggests that altered mitochondrial metabolism plays a critical role in glioblastoma progression, treatment resistance, and tumor adaptation.

The ongoing Phase 2 study builds upon prior clinical and translational research evaluating BPM31510 across oncology indications and reflects BPGbio’s broader focus on targeting mitochondrial dysfunction in diseases with significant unmet medical need.

"Glioblastoma remains one of the most devastating cancers, with limited therapeutic advances for patients in recent decades," said Niven R. Narain, Ph.D, President and Chief Executive Officer of BPGbio. "We believe mitochondrial targeting represent an important and underexplored therapeutic frontier in GBM in oncology. BPM31510 is designed to target the mitochondrial metabolism that cancer cells depend upon, increasing OXPHOS and ROS, restoring apoptotic potential to a cancer cell. The emerging data in this study is encouraging, and we look forward to sharing updates with the community at ASCO (Free ASCO Whitepaper)."

About BPM31510
BPM31510 is an investigational first-in-class mitochondrial therapeutic consisting of a lipid nano dispersion formulation of oxidized CoQ10 designed to modulate mitochondrial metabolism. BPM31510 is being evaluated across oncology and rare disease indications, including glioblastoma multiforme (GBM), pancreatic cancer, and Primary CoQ10 Deficiency (PCQD). BPM31510 has received Orphan Drug Designation and Pediatric Rare Disease Designation from the U.S. Food and Drug Administration for multiple indications.

(Press release, BPGbio, MAY 28, 2026, View Source [SID1234666182])

On May 28, 2026 Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, reported that the Company will participate in the following investor events during the month of June.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details are as follows:

Jefferies Global Healthcare Conference
Date: Thursday, June 4, 2026
Time: 8:45 AM ET
Webcast Link: View Source

Goldman Sachs 47th Annual Global Healthcare Conference
Date: Tuesday, June 9, 2026
Time: 8:00 AM ET
Webcast Link: View Source

Virtual/Replay availability: Presentations will be archived on Compass’ Events page.

Compass’ management will be available for one-on-one meetings during all events. Interested investors should contact their respective representatives to request meetings.

(Press release, Compass Therapeutics, MAY 28, 2026, View Source [SID1234666181])